Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
COVID-19
100%
Melanoma
66%
Clinical Trial
63%
Immune Checkpoint Inhibitor
60%
Human immunodeficiency virus
43%
Diseases
39%
Beta Cell
39%
Nivolumab
37%
Ipilimumab
37%
Immunotherapy
34%
Infection
33%
Adverse Event
32%
Low Drug Dose
30%
Pembrolizumab
26%
Neoplasm
25%
Intratumoral Drug Administration
24%
Severe Acute Respiratory Syndrome Coronavirus 2
23%
Immune-Related Adverse Events
23%
Glioblastoma
21%
Virus
21%
Insulin Dependent Diabetes Mellitus
20%
Myeloid Dendritic Cell
20%
Trametinib
19%
Dabrafenib
19%
Solid Malignant Neoplasm
18%
Implant
17%
Autoimmunity
16%
Avelumab
16%
Talimogene Laherparepvec
16%
Antimicrobial Agent
16%
Programmed Death-Ligand 1
16%
Overall Survival
16%
Diabetes Mellitus
15%
Quality of Life
15%
Prevalence
15%
Non Small Cell Lung Cancer
15%
Biological Marker
15%
Recurrent Disease
14%
Metastatic Melanoma
14%
Systematic Review
14%
Thyroid Gland
14%
Influenza
13%
Continuous Hemofiltration
13%
Positron Emission Tomography-Computed Tomography
13%
Magnetic Resonance Imaging
13%
Brugada Syndrome
13%
MEK Inhibitor
12%
Respiratory Tract Infection
12%
Lymphadenopathy
12%
Biopsy Technique
12%
CTLA-4
12%
Retrospective Study
12%
Heart Ventricle Arrhythmia
12%
Cancer
12%
Oral
11%
Corticosteroid
11%
Long Term Survival
11%
Monoclonal Antibody
11%
Urinary Tract Infection
11%
Intensive Care Unit
11%
Glucose
11%
Superinfection
11%
Messenger RNA
11%
Antibiotic Resistance
11%
Differential Diagnosis
11%
Monotherapy
11%
Thyroid Disease
11%
Comorbidity
10%
Sarcoidosis
10%
Injection
10%
Pancreatic Islet
10%
Genetics
10%
Drug Megadose
10%
Pre-Exposure Prophylaxis
10%
Skin Toxicity
10%
Evolution
10%
Programmed Death 1 Receptor
10%
Adjuvant Therapy
10%
Immunosuppressive Treatment
10%
Antiretroviral Therapy
10%
Cryoablation
10%
Pontiac Fever
10%
Mitral Annulus
10%
Omentum
10%
Gut Microbiome
9%
Health Care Cost
9%
Tumor
9%
Dyspnea
9%
Retrospective Cohort Study
9%
Side Effect
9%
Malignant Neoplasm
9%
Progression Free Survival
9%
Pathogen
9%
Tertiary Care
8%
Antibiotic Therapy
8%
Omicron Coronavirus Variant
8%
Hypophysitis
8%
Antimicrobial Stewardship
8%
Combination Therapy
8%
Stem Cell
8%
Immunology and Microbiology
Infection
82%
Infectious Disease
82%
COVID-19
65%
Human immunodeficiency virus
44%
Human Immunodeficiency Virus 1
40%
Severe Acute Respiratory Syndrome Coronavirus 2
36%
Dendritic Cell
35%
Immunotherapy
34%
Immune Checkpoint Inhibitor
33%
Pembrolizumab
32%
Blood Plasma
23%
Metabolic Tumor Volume
23%
Positron Emission Tomography-Computed Tomography
22%
T Cell
22%
Peptides
19%
Talimogene Laherparepvec
18%
Myeloid Dendritic Cell
18%
Overall Survival
18%
In Vitro
17%
Lung
15%
Cytokine
14%
Multiple Myeloma
13%
Nivolumab
12%
Immune Response
12%
Human Immunodeficiency Virus Infection
12%
Viral Load
11%
Prevalence
11%
Progression Free Survival
11%
Antimicrobial Agent
11%
Ribonucleic Acid
11%
Evolution
10%
Cytotoxic T-Cell
10%
Influenza
10%
Monoclonal Antibody
10%
Monkeypox
10%
Gut Microbiome
9%
CD4 Lymphocyte Count
9%
Real-Time Polymerase Chain Reaction
9%
Omicron Coronavirus Variant
9%
Virus
9%
CTLA-4
9%
Maturation
9%
Natural Killer Cell
9%
Ipilimumab
9%
Minimum Inhibitory Concentration
9%
Antigen
9%
Cell Death
8%
Immunosuppressant
8%
Humoral Immunity
8%
Natural Killer T Cell
8%
Autoimmunity
7%
Insulin
7%
Programmed Death-Ligand 1
7%
Low Drug Dose
7%
Immunogenicity
7%
Autoantibody
7%
Intravenous Immunoglobulin
7%
Antibiotic Resistance
7%
Immune Checkpoint Blockade
7%
Neutrophil
7%
Regulatory T Cell
7%
Cell Function
6%
C-Reactive Protein
6%
Coccidioides
6%
HIV Vaccine
6%
Urinary Tract
6%
Seroprevalence
6%
Leptin Receptor
6%
Early Secretory Antigenic Target 6
6%
Hemagglutinin
6%
Endometrium Cancer
6%
Uterine Cancer
6%
Antigen Specificity
6%
Serology
6%
Polymerase Chain Reaction
6%
Infectious Agent
6%
Real Time Polymerase Chain Reaction
5%
Whole Genome Sequencing
5%
Wild Type
5%
Gene Expression Assay
5%
Spike
5%
Central Nervous System
5%
Epitope
5%
Pharmacokinetic
5%
Drug Megadose
5%
Immunocompromised Patient
5%
Programmed Death 1 Receptor
5%
Monocyte
5%
Viral Reservoir
5%
Respiratory Virus
5%
Mediator
5%
Glucose
5%
Sarcoidosis
5%
Pseudomonas aeruginosa
5%
Drug Resistance
5%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
49%
Melanoma
41%
Adverse Event
41%
Immune Checkpoint Inhibitor
36%
HIV
36%
Ipilimumab
24%
Antimicrobial Agent
23%
Nivolumab
22%
Infection
22%
Solid Malignant Neoplasm
22%
Diseases
21%
Neoplasm
20%
Dabrafenib
20%
Trametinib
20%
Immunotherapy
17%
Influenza
16%
Pembrolizumab
14%
Malignant Neoplasm
14%
Avelumab
13%
Replacement Therapy
12%
Polyethylene Terephthalate
12%
Non Small Cell Lung Cancer
11%
Observational Study
11%
Prevalence
10%
Superinfection
10%
Respiratory Tract Infection
10%
Placebo
10%
SARS Coronavirus
10%
Antibiotic Resistance
10%
Lactam
10%
Heart Ventricle Arrhythmia
10%
Antiinfective Agent
9%
Skin Toxicity
9%
Messenger RNA
8%
Tolerability
8%
Immunogenicity
8%
Respiratory Tract
8%
Pharmacokinetic
8%
Progression Free Survival
8%
Overall Survival
8%
Rash
8%
Glucose
8%
Vaccination
8%
Monotherapy
7%
Severe Acute Respiratory Syndrome
7%
Mitogen Activated Protein Kinase Kinase Inhibitor
7%
Coronavirinae
7%
Urinary Tract Infection
7%
Recurrent Disease
7%
Cytotoxic T Lymphocyte Antigen 4
7%
Influenza A (H1N1)
7%
Virus
7%
Human Immunodeficiency Virus 1 Infection
7%
Cohort Study
6%
Glioblastoma
6%
Metastatic Melanoma
6%
Carcinogenicity
6%
Rilpivirine
6%
Brugada Syndrome
6%
Lamivudine
6%
Atrial Fibrillation
6%
Dolutegravir
6%
Mannose Receptor
6%
Nanobody
6%
Goiter
6%
Urokinase
6%
Microbiome
6%
Ulcerative Colitis
6%
Live Attenuated Influenza Vaccine
6%
Defined Daily Dose
6%
Glucocorticoid
6%
Influenza A Virus (H3N2)
6%
Biological Marker
6%
Peptide
6%
Hemodialysis
5%
Diabetes Mellitus
5%
Cytokine
5%
Therapeutic Drug Monitoring
5%
Cefepime
5%
Pharmacodynamics
5%
Fibrosis
5%
Epidemiology
5%
Beta Lactam Antibiotic
5%
Combination Therapy
5%
Meropenem
5%
Antigen
5%